Allogeneic hematopoietic stem cell transplantation in therapy-related myeloid neoplasms (t-MN) of the adult

Monocentric observational study and review of the literature

Elisabetta Metafuni, Patrizia Chiusolo, Luca Laurenti, Federica Sorà, Sabrina Giammarco, Andrea Bacigalupo, Giuseppe Leone, Simona Sica

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Therapy related myeloid neoplasms (t-MN) occur due to direct mutational events of chemotherapeutic agents and radiotherapy. Disease latency, mutational events and prognosis vary with drugs categories. Methods: We describe a cohort of 30 patients, 18 females and 12 males, with median age of 52.5 years (range, 20 to 64), submitted to allogeneic stem cell transplantation (HSCT) in our department between September 1999 and March 2017. Patients had a history of solid tumour in 14 cases, haematological disease in 15 cases and both of them in one case. After a median of 36.5 months (range, 4 to 190) from first neoplasm, patients developed t-AML in 19 cases and t-MDS in 11 cases. Molecular abnormalities were detected in 5 patients, while karyotype aberrations were found in 17 patients. Patients received conventional chemotherapy in 14 cases, azacitidine in 10 cases and both of them in one case. Five patients were submitted to HSCT without previous treatment except for supportive therapy. Results: Seventeen patients obtained sustained CR after SCT, while 8 patients showed resistant or relapsed disease. The remaining five patients died early after SCT. At follow up time (May 2017) 13 patients were alive with a median OS of 48 months (range 3-195), while 17 patients died after a median of 4 months (range 1-27) by relapse mortality in 6 cases and non-relapse mortality in the other 11 patients. Conclusions: Global OS was 43%. After SCT, 72.2% of patients with t-MN maintained a sustained CR.

Original languageEnglish
Article numbere2018005
JournalMediterranean Journal of Hematology and Infectious Diseases
Volume10
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Second Primary Neoplasms
Hematopoietic Stem Cell Transplantation
Observational Studies
Azacitidine
Mortality
Hematologic Diseases
Stem Cell Transplantation
Karyotype
Neoplasms

Keywords

  • Hematopoietic stem cell transplantation
  • Secondary leukemia
  • Therapy-related myeloid neoplasm

ASJC Scopus subject areas

  • Hematology
  • Infectious Diseases

Cite this

@article{7fff5e1dc6a440298b09972af7a971ab,
title = "Allogeneic hematopoietic stem cell transplantation in therapy-related myeloid neoplasms (t-MN) of the adult: Monocentric observational study and review of the literature",
abstract = "Background: Therapy related myeloid neoplasms (t-MN) occur due to direct mutational events of chemotherapeutic agents and radiotherapy. Disease latency, mutational events and prognosis vary with drugs categories. Methods: We describe a cohort of 30 patients, 18 females and 12 males, with median age of 52.5 years (range, 20 to 64), submitted to allogeneic stem cell transplantation (HSCT) in our department between September 1999 and March 2017. Patients had a history of solid tumour in 14 cases, haematological disease in 15 cases and both of them in one case. After a median of 36.5 months (range, 4 to 190) from first neoplasm, patients developed t-AML in 19 cases and t-MDS in 11 cases. Molecular abnormalities were detected in 5 patients, while karyotype aberrations were found in 17 patients. Patients received conventional chemotherapy in 14 cases, azacitidine in 10 cases and both of them in one case. Five patients were submitted to HSCT without previous treatment except for supportive therapy. Results: Seventeen patients obtained sustained CR after SCT, while 8 patients showed resistant or relapsed disease. The remaining five patients died early after SCT. At follow up time (May 2017) 13 patients were alive with a median OS of 48 months (range 3-195), while 17 patients died after a median of 4 months (range 1-27) by relapse mortality in 6 cases and non-relapse mortality in the other 11 patients. Conclusions: Global OS was 43{\%}. After SCT, 72.2{\%} of patients with t-MN maintained a sustained CR.",
keywords = "Hematopoietic stem cell transplantation, Secondary leukemia, Therapy-related myeloid neoplasm",
author = "Elisabetta Metafuni and Patrizia Chiusolo and Luca Laurenti and Federica Sor{\`a} and Sabrina Giammarco and Andrea Bacigalupo and Giuseppe Leone and Simona Sica",
year = "2018",
month = "1",
day = "1",
doi = "10.4084/MJHID.2018.005",
language = "English",
volume = "10",
journal = "Mediterranean Journal of Hematology and Infectious Diseases",
issn = "2035-3006",
publisher = "Universita Cattolica del Sacro Cuore",
number = "1",

}

TY - JOUR

T1 - Allogeneic hematopoietic stem cell transplantation in therapy-related myeloid neoplasms (t-MN) of the adult

T2 - Monocentric observational study and review of the literature

AU - Metafuni, Elisabetta

AU - Chiusolo, Patrizia

AU - Laurenti, Luca

AU - Sorà, Federica

AU - Giammarco, Sabrina

AU - Bacigalupo, Andrea

AU - Leone, Giuseppe

AU - Sica, Simona

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Therapy related myeloid neoplasms (t-MN) occur due to direct mutational events of chemotherapeutic agents and radiotherapy. Disease latency, mutational events and prognosis vary with drugs categories. Methods: We describe a cohort of 30 patients, 18 females and 12 males, with median age of 52.5 years (range, 20 to 64), submitted to allogeneic stem cell transplantation (HSCT) in our department between September 1999 and March 2017. Patients had a history of solid tumour in 14 cases, haematological disease in 15 cases and both of them in one case. After a median of 36.5 months (range, 4 to 190) from first neoplasm, patients developed t-AML in 19 cases and t-MDS in 11 cases. Molecular abnormalities were detected in 5 patients, while karyotype aberrations were found in 17 patients. Patients received conventional chemotherapy in 14 cases, azacitidine in 10 cases and both of them in one case. Five patients were submitted to HSCT without previous treatment except for supportive therapy. Results: Seventeen patients obtained sustained CR after SCT, while 8 patients showed resistant or relapsed disease. The remaining five patients died early after SCT. At follow up time (May 2017) 13 patients were alive with a median OS of 48 months (range 3-195), while 17 patients died after a median of 4 months (range 1-27) by relapse mortality in 6 cases and non-relapse mortality in the other 11 patients. Conclusions: Global OS was 43%. After SCT, 72.2% of patients with t-MN maintained a sustained CR.

AB - Background: Therapy related myeloid neoplasms (t-MN) occur due to direct mutational events of chemotherapeutic agents and radiotherapy. Disease latency, mutational events and prognosis vary with drugs categories. Methods: We describe a cohort of 30 patients, 18 females and 12 males, with median age of 52.5 years (range, 20 to 64), submitted to allogeneic stem cell transplantation (HSCT) in our department between September 1999 and March 2017. Patients had a history of solid tumour in 14 cases, haematological disease in 15 cases and both of them in one case. After a median of 36.5 months (range, 4 to 190) from first neoplasm, patients developed t-AML in 19 cases and t-MDS in 11 cases. Molecular abnormalities were detected in 5 patients, while karyotype aberrations were found in 17 patients. Patients received conventional chemotherapy in 14 cases, azacitidine in 10 cases and both of them in one case. Five patients were submitted to HSCT without previous treatment except for supportive therapy. Results: Seventeen patients obtained sustained CR after SCT, while 8 patients showed resistant or relapsed disease. The remaining five patients died early after SCT. At follow up time (May 2017) 13 patients were alive with a median OS of 48 months (range 3-195), while 17 patients died after a median of 4 months (range 1-27) by relapse mortality in 6 cases and non-relapse mortality in the other 11 patients. Conclusions: Global OS was 43%. After SCT, 72.2% of patients with t-MN maintained a sustained CR.

KW - Hematopoietic stem cell transplantation

KW - Secondary leukemia

KW - Therapy-related myeloid neoplasm

UR - http://www.scopus.com/inward/record.url?scp=85040529128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040529128&partnerID=8YFLogxK

U2 - 10.4084/MJHID.2018.005

DO - 10.4084/MJHID.2018.005

M3 - Article

VL - 10

JO - Mediterranean Journal of Hematology and Infectious Diseases

JF - Mediterranean Journal of Hematology and Infectious Diseases

SN - 2035-3006

IS - 1

M1 - e2018005

ER -